PMID- 32682963
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 319
DP  - 2020 Nov 15
TI  - Effectiveness of alcohol septal ablation for hypertrophic obstructive 
      cardiomyopathy in patients with late gadolinium enhancement on cardiac magnetic 
      resonance.
PG  - 101-105
LID - S0167-5273(20)33427-6 [pii]
LID - 10.1016/j.ijcard.2020.06.049 [doi]
AB  - BACKGROUND: According to European guidelines, alcohol septal ablation (ASA) for 
      hypertrophic obstructive cardiomyopathy (HOCM) may be less effective in patients 
      with extensive septal scarring on cardiac magnetic resonance (CMR). This study 
      aimed to analyze the impact of late gadolinium enhancement (LGE) on CMR on the 
      effectiveness of ASA. METHOD: We conducted an observational retrospective study 
      involving adult patients with symptomatic drug-refractory HOCM who underwent CMR 
      before ASA at two European centres from May 2010 through June 2019. Patients were 
      compared in binary format based on LGE presence. Moreover, a subanalysis focused 
      on patients with septal fibrosis was performed. The effectiveness of ASA was 
      evaluated by echocardiographic, ECG and clinical findings. RESULTS: Of the 113 
      study patients, 54 (48%) had LGE on CMR. The LGE quantification performed in 29 
      patients revealed septal fibrosis in 17. The mean follow-up was 4.4 +/- 2.6 years. 
      Baseline parameters were similar between groups except for basal septal thickness 
      that was greater in LGE+ group (21.1 +/- 3.9 mm for LGE+ vs. 19.2 +/- 3.2 mm for 
      LGE-: p = .005). ASA improved symptoms in all groups and reduced left ventricular 
      outflow tract obstruction (LVOTO) (delta gradient reduction: LGE+: 62 +/- 37.3%; 
      septal LGE+: 75.6 +/- 20.8%; LGE-: 72.5 +/- 21.0%). However, 13% of the LGE+ and 2% 
      of the LGE- group had residual LVOTO above 30 mmHg (p = .027). CONCLUSION: ASA 
      was effective in all patients with HOCM, whether they had LGE on CMR or not and 
      whether they had septal fibrosis or not.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Polakova, Eva
AU  - Polakova E
AD  - Department of Cardiology, Second Medical School, Charles University, Motol 
      University Hospital, Prague, Czech Republic. Electronic address: 
      eva.polakova@fnmotol.cz.
FAU - Liebregts, Max
AU  - Liebregts M
AD  - Department of Cardiology, St.Antonius Hospital, Nieuwegein, the Netherlands.
FAU - Markova, Natalia
AU  - Markova N
AD  - Department of Radiology, Second Medical School, Charles University, Motol 
      University Hospital, Prague, Czech Republic.
FAU - Adla, Theodor
AU  - Adla T
AD  - Department of Radiology, Second Medical School, Charles University, Motol 
      University Hospital, Prague, Czech Republic.
FAU - Kara, Basak
AU  - Kara B
AD  - Department of Cardiology, St.Antonius Hospital, Nieuwegein, the Netherlands.
FAU - Ten Berg, Jurrien
AU  - Ten Berg J
AD  - Department of Cardiology, St.Antonius Hospital, Nieuwegein, the Netherlands.
FAU - Bonaventura, Jiri
AU  - Bonaventura J
AD  - Department of Cardiology, Second Medical School, Charles University, Motol 
      University Hospital, Prague, Czech Republic.
FAU - Veselka, Josef
AU  - Veselka J
AD  - Department of Cardiology, Second Medical School, Charles University, Motol 
      University Hospital, Prague, Czech Republic.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200717
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Contrast Media)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
MH  - *Cardiomyopathy, Hypertrophic/diagnostic imaging/surgery
MH  - Contrast Media
MH  - *Gadolinium
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Alcohol septal ablation
OT  - Cardiac magnetic resonance
OT  - Hypertrophic cardiomyopathy
OT  - Late gadolinium enhancement
OT  - Septal fibrosis
OT  - Septal scarring
EDAT- 2020/07/20 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - S0167-5273(20)33427-6 [pii]
AID - 10.1016/j.ijcard.2020.06.049 [doi]
PST - ppublish
SO  - Int J Cardiol. 2020 Nov 15;319:101-105. doi: 10.1016/j.ijcard.2020.06.049. Epub 
      2020 Jul 17.